Ex-Genzyme ops chief joins board at bio start-up

Manufacturing ops veteran Scott Canute has joined the board at biotech start-up Oncobiologics. Canute, recently president for global manufacturing and corporate ops at Genzyme, was brought in to remediate operations at the biotech's Boston-area plant.

Canute is also former president for global manufacturing ops at Eli Lilly ($LLY), according to an announcement. He brings 30 years of biopharma production expertise to the startup, which is holding a grand opening event at its Cranbury, NJ headquarters this Friday, October 14, 2011.

In early 2010, Canute joined Genzyme as part of a high-level operations restructuring at the facility where a virus contaminated a bioreactor, leading to a plant shutdown for decontamination.  Canute was teamed with Ron Branning, former head of quality and compliance at Gilead Sciences ($GILD), Sandra Poole as senior VP and site leader, and consultancy Quantic Group for manufacturing operations. Remediation work is still underway.

Canute left Genzyme in July, says Boston.com, after it became a unit of Sanofi ($SNY) and the French drug giant transferred oversight of all Genzyme manufacturing ops to Bill Aitchison, former manufacturing head at Sanofi Pasteur vaccines.

- here's the release
- see the story

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.